Biogen Idec (NASDAQ:BIIB)‘s stock had its “buy” rating reiterated by analysts at TheStreet in a research report issued to clients and investors on Monday, Stock Ratings Network.com reports.
The analysts wrote, “Biogen Idec (BIIB) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.”
In other Biogen Idec news, SVP Raymond Pawlicki sold 4,000 shares of Biogen Idec stock on the open market in a transaction dated Friday, November 22nd. The shares were sold at an average price of $288.00, for a total transaction of $1,152,000.00. Following the transaction, the senior vice president now directly owns 8,710 shares of the company’s stock, valued at approximately $2,508,480. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Biogen Idec (NASDAQ:BIIB) opened at 290.97 on Monday. Biogen Idec has a 1-year low of $139.72 and a 1-year high of $297.98. The stock has a 50-day moving average of $250.1 and a 200-day moving average of $230.1. The company has a market cap of $68.731 billion and a price-to-earnings ratio of 40.87.
Biogen Idec (NASDAQ:BIIB) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.35 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.10 by $0.25. The company had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.78 billion. During the same quarter in the prior year, the company posted $1.91 earnings per share. The company’s quarterly revenue was up 31.9% on a year-over-year basis. On average, analysts predict that Biogen Idec will post $8.87 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Piper Jaffray initiated coverage on shares of Biogen Idec in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $331.00 price target on the stock. Separately, analysts at Citigroup Inc. raised their price target on shares of Biogen Idec to $320.00 in a research note to investors on Friday, November 22nd. Finally, analysts at Deutsche Bank raised their price target on shares of Biogen Idec to $340.00 in a research note to investors on Friday, November 22nd. Nine equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Biogen Idec has a consensus rating of “Buy” and an average price target of $267.35.
Biogen Idec Inc (NASDAQ:BIIB) is a global biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.